Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Hoeper, MM; Pausch, C; Grünig, E; Staehler, G; Huscher, D; Pittrow, D; Olsson, KM; Vizza, CD; Gall, H; Distler, O; Opitz, C; Gibbs, JSR; Delcroix, M; Ghofrani, HA; Rosenkranz, S; Park, DH; Ewert, R; Kaemmerer, H; Lange, TJ; Kabitz, HJ; Skowasch, D; Skride, A; Claussen, M; Behr, J; Milger, K; Halank, M; Wilkens, H; Seyfarth, HJ; Held, M; Dumitrescu, D; Tsangaris, I; Vonk-Noordegraaf, A; Ulrich, S; Klose, H.
Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry.
Eur Respir J. 2022; 59(6): Doi: 10.1183/13993003.02024-2021 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Milger-Kneidinger Katrin
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: BACKGROUND: Since 2015, the European pulmonary hypertension guidelines recommend the use of combination therapy in most patients with pulmonary arterial hypertension (PAH). However, it is unclear to what extent this treatment strategy is adopted in clinical practice and if it is associated with improved long-term survival. METHODS: We analysed data from COMPERA, a large European pulmonary hypertension registry, to assess temporal trends in the use of combination therapy and survival of patients with newly diagnosed PAH between 2010 and 2019. For survival analyses, we looked at annualised data and at cumulated data comparing the periods 2010-2014 and 2015-2019. RESULTS: A total of 2531 patients were included. The use of early combination therapy (within 3 months after diagnosis) increased from 10.0% in patients diagnosed with PAH in 2010 to 25.0% in patients diagnosed with PAH in 2019. The proportion of patients receiving combination therapy 1 year after diagnosis increased from 27.7% to 46.3%. When comparing the 2010-2014 and 2015-2019 periods, 1-year survival estimates were similar (89.0% (95% CI 87.2-90.9%) and 90.8% (95% CI 89.3-92.4%), respectively), whereas there was a slight but nonsignificant improvement in 3-year survival estimates (67.8% (95% CI 65.0-70.8%) and 70.5% (95% CI 67.8-73.4%), respectively). CONCLUSIONS: The use of combination therapy increased from 2010 to 2019, but most patients still received monotherapy. Survival rates at 1 year after diagnosis did not change over time. Future studies need to determine if the observed trend suggesting improved 3-year survival rates can be confirmed.
Find related publications in this database (using NLM MeSH Indexing): Familial Primary Pulmonary Hypertension - administration & dosage; Humans - administration & dosage; Hypertension, Pulmonary - drug therapy, epidemiology; Pulmonary Arterial Hypertension - drug therapy, epidemiology; Registries - administration & dosage; Survival Rate - administration & dosage